Your browser is no longer supported. Please, upgrade your browser.
Settings
ADRO Aduro BioTech, Inc. daily Stock Chart
ADRO [NASD]
Aduro BioTech, Inc.
Index- P/E- EPS (ttm)-1.03 Insider Own1.10% Shs Outstand79.80M Perf Week12.75%
Market Cap225.83M Forward P/E- EPS next Y-0.72 Insider Trans-9.29% Shs Float56.44M Perf Month19.92%
Income-82.40M PEG- EPS next Q-0.14 Inst Own44.90% Short Float5.98% Perf Quarter112.78%
Sales17.30M P/S13.05 EPS this Y15.00% Inst Trans0.12% Short Ratio2.77 Perf Half Y183.00%
Book/sh0.81 P/B3.49 EPS next Y4.00% ROA-25.40% Target Price7.33 Perf Year-27.25%
Cash/sh2.68 P/C1.06 EPS next 5Y9.00% ROE-90.50% 52W Range0.90 - 4.59 Perf YTD139.83%
Dividend- P/FCF- EPS past 5Y-30.40% ROI-133.70% 52W High-38.34% Beta0.34
Dividend %- Quick Ratio10.10 Sales past 5Y5.20% Gross Margin- 52W Low214.06% ATR0.33
Employees96 Current Ratio10.10 Sales Q/Q28.60% Oper. Margin- RSI (14)53.35 Volatility10.89% 14.46%
OptionableYes Debt/Eq0.00 EPS Q/Q27.30% Profit Margin- Rel Volume0.41 Prev Close2.70
ShortableYes LT Debt/Eq0.00 EarningsMar 04 Payout- Avg Volume1.22M Price2.83
Recom2.20 SMA2011.42% SMA502.52% SMA20074.98% Volume494,502 Change4.81%
Jan-10-20Downgrade Cowen Outperform → Market Perform
Dec-18-19Downgrade William Blair Outperform → Mkt Perform
Jun-03-19Downgrade Oppenheimer Outperform → Perform
Apr-15-19Initiated SVB Leerink Outperform $9
Feb-22-18Initiated Cantor Fitzgerald Overweight $15
Dec-13-17Reiterated H.C. Wainwright Buy $18 → $9.50
May-01-17Initiated Rodman & Renshaw Buy $18
May-17-16Reiterated FBR Capital Outperform $30 → $22
Mar-15-16Downgrade BofA/Merrill Buy → Underperform $32 → $14
Mar-02-16Initiated FBR Capital Outperform $30
Dec-01-15Downgrade Oppenheimer Outperform → Perform
Nov-24-15Reiterated ROTH Capital Buy $74 → $68
Oct-20-15Initiated Oppenheimer Outperform $30
May-11-15Initiated Leerink Partners Outperform $48
May-11-15Initiated Canaccord Genuity Buy $43
May-11-15Initiated BofA/Merrill Buy $40
Apr-20-15Initiated ROTH Capital Buy $74
Apr-08-20 11:30AM  Aduro Biotech (ADRO) Down 3.1% Since Last Earnings Report: Can It Rebound? Zacks +8.43%
Apr-03-20 05:50PM  Aduro Biotech (ADRO) Gains As Market Dips: What You Should Know Zacks
Apr-01-20 11:30AM  Has Aduro Biotech (ADRO) Outpaced Other Medical Stocks This Year? Zacks -11.68%
Mar-23-20 05:50PM  Aduro Biotech (ADRO) Gains As Market Dips: What You Should Know Zacks
Mar-16-20 11:30AM  Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year? Zacks -10.55%
Mar-11-20 02:20PM  Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4 Zacks -8.17%
Mar-09-20 05:55PM  Aduro Biotech (ADRO) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:15PM  Aduro Biotech Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Mar-05-20 05:50PM  Aduro Biotech (ADRO) Stock Moves -0.6%: What You Should Know Zacks
Feb-28-20 11:30AM  Is Aduro Biotech (ADRO) Stock Outpacing Its Medical Peers This Year? Zacks
Feb-24-20 04:15PM  Aduro Biotech to Present at the Cowen and Company 40th Annual Health Care Conference GlobeNewswire
Feb-19-20 12:31PM  Aduro Biotech (ADRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
12:00PM  Aduro Biotech (ADRO) Upgraded to Strong Buy: Here's Why Zacks
08:15AM  Aduro Biotech to Present at the 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-06-20 04:15PM  Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer GlobeNewswire -8.18%
Jan-10-20 06:03PM  East Bay cancer drug developer, jilted by Novartis, to cut 51 jobs American City Business Journals -10.53%
06:00PM  Biotechs punch up talking points leading into big Union Square conference American City Business Journals
Jan-09-20 04:15PM  Aduro Biotech Announces Corporate Restructuring GlobeNewswire
Dec-14-19 05:18PM  Hedge Funds Are Betting On Aduro BioTech Inc (ADRO) Insider Monkey
Dec-09-19 05:06AM  Does Aduro BioTech, Inc. (NASDAQ:ADRO) Have A Volatile Share Price? Simply Wall St.
Dec-07-19 11:31AM  Aduro Biotech (ADRO) Up 7.5% Since Last Earnings Report: Can It Continue? Zacks
Nov-08-19 04:05PM  Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting GlobeNewswire +10.28%
12:20PM  Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y Zacks
Nov-07-19 07:35PM  Aduro Biotech (ADRO) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM  Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-25-19 07:49AM  Should You Worry About Aduro BioTech, Inc.'s (NASDAQ:ADRO) CEO Pay? Simply Wall St.
Oct-02-19 04:05PM  Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019) GlobeNewswire
Sep-30-19 04:05PM  Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-19-19 09:49AM  Do Insiders Own Lots Of Shares In Aduro BioTech, Inc. (NASDAQ:ADRO)? Simply Wall St.
Sep-04-19 08:30AM  Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) GlobeNewswire
Sep-03-19 04:05PM  Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire
Aug-31-19 09:31AM  Why Is Aduro Biotech (ADRO) Down 12.1% Since Last Earnings Report? Zacks
Aug-14-19 02:32PM  Who Has Been Selling Aduro BioTech, Inc. (NASDAQ:ADRO) Shares? Simply Wall St.
Aug-05-19 10:46AM  Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates Zacks -6.67%
Aug-01-19 04:05PM  Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results GlobeNewswire +6.06%
Jul-31-19 10:36AM  Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-16-19 11:04AM  AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio Zacks
Jun-04-19 10:32AM  Aduro Stock Crashes After ASCO Updates on Cancer Candidate Zacks
Jun-02-19 11:45AM  Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas GlobeNewswire
May-20-19 04:53PM  Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea American City Business Journals
May-15-19 05:06PM  Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire
05:05PM  Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301 GlobeNewswire
May-08-19 12:06PM  Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates Zacks -21.09%
May-07-19 06:45PM  Aduro Biotech (ADRO) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:54PM  What's in Store for Axsome (AXSM) This Earnings Season? Zacks
04:05PM  Aduro Biotech Reports First Quarter 2019 Financial Results GlobeNewswire
10:53AM  Guardant Health (GH) to Report Q1 Earnings: What's in Store? Zacks
10:47AM  Proteostasis (PTI) to Post Q1 Earnings: What's in Store? Zacks
May-06-19 04:13PM  Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up? Zacks
03:06PM  What's in the Cards for Perrigo (PRGO) This Earnings Season? Zacks
11:54AM  Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up? Zacks
May-03-19 05:22PM  Mylan (MYL) to Report Q1 Earnings: What's in the Offing? Zacks
10:32AM  What's in Store for Sorrento (SRNE) This Earnings Season? Zacks
May-02-19 10:58AM  PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store? Zacks
May-01-19 06:07PM  Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings? Zacks
Apr-30-19 11:39AM  AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up? Zacks
09:15AM  Small Gains Still Bring New Highs Zacks
08:16AM  What's in the Cards for Bausch Health (BHC) Q1 Earnings? Zacks
Apr-29-19 06:14PM  Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings? Zacks
Apr-28-19 11:52PM  Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock? Zacks
10:47PM  Is a Beat in the Cards for Molina's (MOH) Earnings in Q1? Zacks
Apr-26-19 11:48AM  Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates Zacks
11:42AM  What's in Store for HCA Healthcare's (HCA) Q1 Earnings? Zacks
11:38AM  Is a Beat in Store for WellCare Health's (WCG) Q1 Earnings? Zacks
Apr-25-19 11:55AM  Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store? Zacks
11:15AM  Is a Beat in Store for Editas (EDIT) This Earnings Season? Zacks
09:27AM  The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences Zacks
Apr-24-19 04:32PM  What's in Store for Vertex (VRTX) This Earnings Season? Zacks
12:06PM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
11:43AM  Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock? Zacks
11:25AM  Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y Zacks
10:33AM  Aduro Biotech (ADRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
09:11AM  5 Biotech Stocks Defying the Medicare-for-All Scare Zacks
Apr-22-19 11:08AM  Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store? Zacks
10:33AM  Is a Beat in Store for AbbVie (ABBV) This Earnings Season? Zacks
08:15AM  Aduro Biotech Appoints Dimitry S.A. Nuyten, M.D., Ph.D. as Chief Medical Officer GlobeNewswire
Apr-18-19 04:05PM  Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors GlobeNewswire
Apr-17-19 04:05PM  Aduro Biotech Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire -7.59%
Apr-08-19 08:47AM  What Kind Of Shareholders Own Aduro BioTech, Inc. (NASDAQ:ADRO)? Simply Wall St.
Apr-01-19 08:00AM  Aduro Biotech to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-27-19 10:48AM  Lilly (LLY) Signs New Immunology Deal With Private Biotech Zacks
Mar-07-19 08:00AM  Aduro Biotech to Present at Two Upcoming Investor Conferences in March GlobeNewswire
Mar-01-19 10:27AM  The Meet Group (MEET) to Report Q4 Earnings: What's in Store? Zacks
09:18AM  What Should We Expect From Aduro BioTech, Inc.s (NASDAQ:ADRO) Earnings In The Years Ahead? Simply Wall St.
Feb-28-19 04:13PM  Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates Zacks
09:07AM  Top Ranked Momentum Stocks to Buy for February 28th Zacks
08:00AM  Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019 GlobeNewswire
Feb-27-19 04:05PM  Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
09:36AM  Top Ranked Momentum Stocks to Buy for February 27th Zacks
Feb-25-19 09:10AM  Will Aduro Biotech Continue to Surge Higher? Zacks
09:02AM  What's in Store for Universal Health (UHS) Q4 Earnings? Zacks
07:26AM  Top Ranked Momentum Stocks to Buy for February 25th Zacks
Feb-22-19 04:43PM  What's in Store for Vericel (VCEL) This Earnings Season? Zacks
Feb-21-19 08:55AM  Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings? Zacks +5.70%
08:15AM  Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
08:00AM  Aduro Announces Changes to its Board of Directors GlobeNewswire
Feb-20-19 08:54AM  Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings? Zacks
07:35AM  What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings? Zacks
Feb-19-19 10:07AM  What's in Store for Sangamo (SGMO) This Earnings Season? Zacks
Feb-14-19 10:45AM  The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna Zacks
Aduro BioTech, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy and multiple myeloma; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and NK cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greenman William MarinerDirectorMar 18Option Exercise0.4519,8358,92619,835Mar 20 05:18 PM
van Elsas AndreaChief Scientific OfficerFeb 25Sale3.516,82323,954438,367Feb 26 06:58 PM
van Elsas AndreaChief Scientific OfficerJan 03Sale1.1973,31187,108445,190Jan 06 06:38 PM
Templeman BlaineChief Legal OfficerDec 12Sale1.161,2641,470117,736Dec 16 04:14 PM
van Elsas AndreaChief Scientific OfficerDec 12Sale1.162,1922,550518,501Dec 16 04:13 PM
Ferber CelesteSVP, GC and SecretaryDec 12Sale1.1640847526,534Dec 16 04:13 PM
ISAACS STEPHEN TPresident and CEODec 12Sale1.165,8976,860290,029Dec 16 04:12 PM
Haghighat RossDirectorSep 16Option Exercise0.6455,53935,52787,122Sep 18 07:00 PM
ISAACS STEPHEN TPresident and CEOSep 13Sale1.3131,09840,608295,926Sep 17 06:34 PM
Ferber CelesteSVP, GC and SecretarySep 13Sale1.312,4943,25726,942Sep 17 06:34 PM
van Elsas AndreaChief Scientific OfficerSep 13Sale1.3118,59324,279520,693Sep 17 06:33 PM
Templeman BlaineChief Legal OfficerSep 13Sale1.3112,87816,817117,000Sep 17 06:32 PM
Ferber CelesteSVP, GC and SecretaryMay 20Sale3.212,0006,41329,436May 22 07:04 PM
Lew JenniferChief Financial OfficerMay 01Option Exercise1.2518,60223,306147,299May 03 07:17 PM
Lew JenniferChief Financial OfficerMay 01Sale4.2018,60278,136135,155May 03 07:17 PM